¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lowry assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    Ãʰú»êÈ­¹°ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    °ú»êÈ­¹°ÃøÁ¤
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
  • hemizona assay index
    ¹ÝÅõ¸í¶ìÃøÁ¤ÁöÇ¥
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigenic assay
    Ç׿ø¼ººÐ¼®
  • antimicobial assay
    Ç×±ÕÁ¦ÃøÁ¤
  • growth hormone assay
    ¼ºÀåÈ£¸£¸óÃøÁ¤
  • hemizona assay (index)
    ¹ÝÅõ¸í´ë ÃøÁ¤(ÁöÇ¥)
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • immunoconcentration assay
    ¸é¿ª³óÃàÃøÁ¤<--Á¤·®
  • immunoenzymometric assay
    ¸é¿ªÈ¿¼Ò°èÃø<--°è·®>ºÐ¼®
  • immunofluorescence assay
    ¸é¿ªÇü±¤°Ë»ç
  • immunometric assay
    ¸é¿ª°è·®<--°èÃø>°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • plaque assay
    ÇöóÅ© ÃøÁ¤¹ý
  • plaque assay, hemolytic
    ¿ëÇ÷¼º ÇöóÅ© Çü¼º½ÃÇè
  • predictive assay
    È¿°ú¿¹Ãø½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • biological assay
    »ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ)
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • calcitonin assay
    Ä®½ÃÅä´ÑÃøÁ¤
  • carcinoembryonic antigen assay
    ¾Ï(¼º)¹è¾Æ¼º Ç׿øÃøÁ¤
  • cell adhesive matrix assay
    ¼¼Æ÷Á¡Âø±âÁúºÐ¼®
  • clonogenic assay
    Ŭ·Ð¿ø¼º ºÐ¼®
  • clonogenic assay
    Ŭ·Ð¿ø¼ººÐ¼®
  • colony formation assay
    Áý¶ôÇü¼º´ÉÃøÁ¤
  • creatine kinase assay
    Å©·¹¾ÆÆ¾Å°³ªÁ¦ÃøÁ¤
  • diagnostic assay
    Áø´ÜÀûºÐ¼®
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
  • enzymatic assay
    È¿¼Ò¾Æ½êÀ̼º ÃøÁ¤(¹ý).
  • enzymatic assay
    È¿¼Ò¼º(ý£áÈàõ) ÃøÁ¤(ö´ïÒ)(¹ý).
  • enzyme linked immunosorbent assay ( ELISA)
    È¿¼Ò ¸é¿ªÃøÁ¤¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • i-assay
    i-¾Æ½êÀÌ
  • immunoenzymometric assay
    ¸é¿ªÈ¿¼ÒÃøÁ¤(Øóæ¹ý£áÈö´ïÒ) ¾Æ½êÀÌ
  • immunofluorometric assay
    ¸é¿ªÇü±¤ÃøÁ¤(Øóæ¹û«ÎÃö´ïÒ) ¾Æ½êÀÌ
  • immunoradiometric assay
    ¸é¿ª¹æ»ç´ÉÃøÁ¤(Øóæ¹Û¯ÞÒÒöö´ïÒ) ¾Æ½êÀÌ
  • in situ hybridization assay
    Á¦ÀÚ¸® Æ¢±â»ý¼º(ßæà÷) ¾Æ½êÀÌ
  • kinetic assay
    ¿ªµ¿(æ³ÔÑ)¾Æ½êÀÌ
  • linked assay
    ¿¬°è(ææÍ¨)¾Æ¼¼ÀÌ
  • linked enzyme assay procedure
    ¿¬°èÈ¿¼Ò(ææÍ¨ý£áÈ) ¾Æ½êÀÌ ¹æ½Ä(Û°ãÒ)
  • microbiological assay
    ¹Ì»ý¹°(Ú°ßæÚª)¾Æ¼¼ÀÌ
  • plaque assay
    ÇöóÅ© ¾Æ½êÀÌ
  • radioisotopic enzyme assay
    ¹æ»ç¼º µ¿À§¿ø¼Ò È¿¼Ò(Û¯ÞÒàõÔÒêÈêªáÈý£áÈ) ¾Æ½êÀÌ
  • rat antidiuresis assay
    Áã Ç×ÀÌ´¢(ù÷××Òã) ¾Æ½êÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LAI assay Leukocyte Adherence Inhibition assay
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
IFA idiopathic fibrosing alveolitis; immunofluorescence assay; immunofluorescent antibody; incomplete Fr...
CPBA Competitive Protein Binding Assay
EIA   1) Exercise Induced Asthma; ¿îµ¿ À¯¹ß¼º õ½Ä
  = EIB
  2) Enzyme Immu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DIG-ELISA Diffusion-In-Gel Enzyme Linked Immunosorbent Assay
DFA Direct immunofluorescence assay
Dot-ELISA Dot Enzyme-Linked Immunosorbent Assay
DIA Dot immunobinding assay
EIA Electro Immuno-Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • microbiological assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • micrologica assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • radioreceptor assay
    ¹æ»ç¼± ¼ö¿ëü ÃøÁ¤¹ý
    ÀÏÁ¾ÀÇ ¹æ»ç Ç¥Áö °ËÁ¤¹ýÀ¸·Î¼­, Á¶Á÷ Ç¥º» ³»¿¡ Àִ ȣ¸£¸ó¿¡ ´ëÇØ Ư¼öÇÑ ¼¼Æ÷ ¼ö¿ëüÀÇ ³óµµ¸¦ ¹æ»ç Ç¥ÁöÇÑ È£¸£¸óÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÏ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
gel retardation assay A lab technique used to find out if there are proteins binding a fragment of DNA (in a DNA-protein complex) by watching how fast the DNA fragment moves through an electric field and seeing whether it moves slower when a particular protein is also present.
(09 Oct 1997)
checkerboard assay <procedure> Variant of the Boyden chamber assay for leucocyte chemotaxis introduced by Zigmond. By testing different concentrations of putative chemotactic factor in nongradient conditions, it is possible to calculate the enhancement of movement expected due simply to chemokinesis and to compare this with the distances moved in positive and negative gradients. Good experimental design thus allows chemotaxis to be distinguished from chemokinesis.
(21 May 1997)
chloramphenicol acetyltransferase assay <investigation> A lab technique used to determine whether a given fragment of DNA has a promoter on it to encourage transcription to occur, by attaching the gene (called the CAT gene) which codes for the CAT enzyme to it, and observing whether the CAT enzyme is produced.
(05 Jan 1998)
Grunstein-Hogness assay A procedure for identifying plasmid clones by colony hybridization.
(05 Mar 2000)
christmas factor assay A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
clonogenic assay In vitro culturing of neoplastic cells to test their radiosensitivity or chemosensitivity, and probable clinical efficacy of a therapeutic agent.
(05 Mar 2000)
colony-forming units assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
(12 Dec 1998)
competitive binding assay General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plaque assay 1. <investigation> Assay for virus in which a dilute solution of the virus is applied to a culture dish containing a layer of the host cells, convective spread is prevented by making the medium very viscous. After incubation the plaques, areas in which cells have been killed (or transformed), can be recognised and the number of infective virus particles in the original suspension estimated.
2. Assay for cells producing antibody against erythrocytes or against antigen that has been bound to the erythrocytes. The cell is surrounded by a clear plaque of haemolysis. Basic principle behind the assay is the same as for the virus plaque assay.
(18 Nov 1997)
haemolytic plaque assay <investigation> A haemolytic plaque assay is a lab technique used to show that certain antibodies are secreted by antibody-making cells when these cells are mixed with red blood cells.
The mixture is spread onto a plate of agar, if a plaque appears, it means that the red blood cells have been destroyed (by haemolysis) by the antibodies.
(09 Oct 1997)
Hageman factor assay A test used to measure the activity of a blood clotting factor XII. This test may be used to evaluate excessive bleeding. Low factor XII may be seen in cases of congenital deficiency of factor XII, heparin administration and liver disease.
(27 Sep 1997)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
hemizona assay <investigation> The hemizona assay is a laboratory test of the ability of sperm to penetrate into a human egg, first the egg is split in half, then one half is tested against the husband's sperm and the other half against sperm from a fertile man.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á